Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

The Value of HPV Genotyping in Cervical Cancer Screening

EF 2011-12

Résumé
It is now well established that human papillomavirus (HPV) is a necessary cause of cervical cancer and the most common sexually transmitted infection (STI) worldwide. Additionally, most sexually active women will acquire HPV infection in their lifetime. While the vast majority of these infections will be transient, a fraction of them will become persistent and may lead to pre-cancerous lesions. Detection of these lesions through screening is critical to the prevention of cervical cancer. While screening approaches have largely relied on Papanicolaou cytology (i.e., the Pap test), molecular techniques detecting HPV DNA have shown greater sensitivity in identifying cervical cancer and cervical intraepithelial neoplasia (CIN). However, the value of qualitatively defining HPV genotypes in cervical specimens, in addition to determining HPV positivity, remains unclear. In an attempt to better prioritize case management and inform risk stratification procedures, we plan to examine whether determining the HPV genotype (via a PCR assay) in cervical specimens helps predict current and future risk of high-grade CIN in primary screening more accurately than simply testing for HPV infection with oncogenic types (via the Hybrid Capture 2 test). This study will use data and samples gathered from the Canadian Cervical Cancer Screening Trial (CCCaST), a CIHR-funded randomized controlled trial that compared the relative efficacy of HPV and Pap testing in primary screening for cervical cancer precursors in Montreal and St. John's, Canada. The proposed study will generate new knowledge regarding the value of HPV DNA testing in primary care screening, and assist the formulation of evidence-based practice guidelines for cervical cancer screening in Canada and elsewhere.
Programme
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
257459
Name
Isidean Sandra D
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
The Value of HPV Genotyping in Cervical Cancer Screening
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Cancer Screening; Cervical Cancer; Epidemiology; Human Papillomavirus
Abstract
It is now well established that human papillomavirus (HPV) is a necessary cause of cervical cancer and the most common sexually transmitted infection (STI) worldwide. Additionally, most sexually active women will acquire HPV infection in their lifetime. While the vast majority of these infections will be transient, a fraction of them will become persistent and may lead to pre-cancerous lesions. Detection of these lesions through screening is critical to the prevention of cervical cancer. While screening approaches have largely relied on Papanicolaou cytology (i.e., the Pap test), molecular techniques detecting HPV DNA have shown greater sensitivity in identifying cervical cancer and cervical intraepithelial neoplasia (CIN). However, the value of qualitatively defining HPV genotypes in cervical specimens, in addition to determining HPV positivity, remains unclear. In an attempt to better prioritize case management and inform risk stratification procedures, we plan to examine whether determining the HPV genotype (via a PCR assay) in cervical specimens helps predict current and future risk of high-grade CIN in primary screening more accurately than simply testing for HPV infection with oncogenic types (via the Hybrid Capture 2 test). This study will use data and samples gathered from the Canadian Cervical Cancer Screening Trial (CCCaST), a CIHR-funded randomized controlled trial that compared the relative efficacy of HPV and Pap testing in primary screening for cervical cancer precursors in Montreal and St. John's, Canada. The proposed study will generate new knowledge regarding the value of HPV DNA testing in primary care screening, and assist the formulation of evidence-based practice guidelines for cervical cancer screening in Canada and elsewhere.
Competitiondate
201110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Isidean, Sandra D
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~